Chapter Eight
Summary
Schizophrenia and other psychotic disorders affect more than 1% of the general population. It is key to assess
and treat schizophrenia in its early stages and to prevent relapse. Patients left untreated in the first year of an episode
can be as much as a 15% suicide risk.
Schizophrenia is not caused by poor parenting, trauma, or other “demonic” possession. Schizophrenia is first
and foremost a brain disorder with numerous abnormalities in structure, function and neurochemistry. With regard to
structure, we find an enlargement of the lateral ventricles followed by decreased volume of gray and white matter.
The medial temporal structures such as the hippocampus and amygdala have also been found to be smaller in size to
non-schizophrenic controls.
The most common neurochemical abnormality involves the “hyperdopaminergic” theory in which refers to
the idea that too much dopamine causes psychotic symptoms. Medications used in the treatment of these conditions
block dopamine D2 receptors at the post-synaptic membrane. Newer atypical antipsychotics block D2 and 5HT
receptors as well, but produce less side effects than the older neuroleptics.
Schizophrenia has a strong familial link with high concordance rates among first-degree relatives. We also
find that the disorder is much more prevalent among those in urban areas, those born in colder months in colder
climates, and among those whose mothers may have had a viral infection during their second trimester of pregnancy.
We also need to be aware that many other medical conditions cause or worsen a patient’s psychotic
symptoms. These include brain tumors, infections, dementia, hormonal abnormalities and metabolic changes. Various
medications can also cause severe personality changes and psychoticism. These include drugs of abuse, pain
medications, steroids, antiparkinsonian drugs, and other environmental toxins.
Specific Discussion Questions:
1. Explain the difference between positive and negative symptoms of schizophrenia.
2. Summarize the various causes of schizophrenia and other psychotic disorders.
3. What are some of the advantages of the newer antipsychotic medications over the older neuroleptics?
4. Explain tardive dyskinesia and why it is problematic. What new medications do we have to address this?